Legend Biotech (LEGN) Position Analysis
Legend Biotech (LEGN) is heading into its latest earnings report with a notable divergence between price performance and short-selling activity. The stock has surged 30% over the past month, yet short interest remains elevated above 8% of the free float. According to Ortex data as of November 10, 2026, the pressure on the stock is primarily commercial rather than governance-driven, as no 13D activist filings are currently on the register. The upcoming print will test whether the commercial trajectory of CARVYKTI is sufficient to justify the recent valuation rerating. While the short interest is not at extreme levels, the combination of a strong rally and persistent bearish bets creates a unique environment for volatility around the earnings announcement.
Signal data sourced from Ortex. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.